STOCK TITAN

Mineralys Therapeutics, Inc. - MLYS STOCK NEWS

Welcome to our dedicated page for Mineralys Therapeutics news (Ticker: MLYS), a resource for investors and traders seeking the latest updates and insights on Mineralys Therapeutics stock.

Mineralys Therapeutics, Inc. (MLYS) is a clinical-stage biopharmaceutical company advancing targeted therapies for hypertension, chronic kidney disease, and sleep apnea. This page aggregates official news and press releases, providing investors with essential updates on the company’s progress in developing aldosterone-focused treatments.

Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships. The curated content includes detailed announcements about lead candidate lorundrostat, a selective aldosterone synthase inhibitor, alongside financial disclosures and market analyses.

Key updates cover:

• Clinical Research: Phase advancements and trial outcomes
• Regulatory Progress: FDA communications and approval pathways
• Corporate Strategy: Collaborations and pipeline expansions
• Financial Updates: Earnings summaries and investment decisions

Bookmark this resource for direct access to primary-source MLYS developments. Visit regularly for objective reporting on innovations in cardiorenal therapeutics.

Rhea-AI Summary
Mineralys Therapeutics, Inc. to participate in Cantor Fitzgerald Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.08%
Tags
conferences
-
Rhea-AI Summary
Mineralys Therapeutics announces positive results from the Target-HTN Phase 2 trial of lorundrostat, a highly selective aldosterone synthase inhibitor, in individuals with uncontrolled and treatment-resistant hypertension. The trial demonstrated a significant, double-digit reduction in systolic blood pressure (BP) with a well-tolerated profile. Subjects with an elevated body mass index (BMI) showed enhanced reduction in systolic BP. The results support further study of lorundrostat as a treatment for hypertension.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Mineralys Therapeutics presents final results from the Target-HTN Phase 2 trial of lorundrostat, demonstrating a robust reduction in systolic blood pressure, particularly in individuals with elevated BMI. Pivotal trials ongoing with topline data expected in 2024 and 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Mineralys Therapeutics to present full results from Target-HTN Phase 2 trial at AHA Hypertension Scientific Sessions
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
-
Rhea-AI Summary
Mineralys Therapeutics to participate in fireside chat at Wells Fargo Securities Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.96%
Tags
Rhea-AI Summary
Mineralys Therapeutics, Inc. (NASDAQ: MLYS) will report its financial results for the second quarter ended June 30, 2023, on August 7, 2023, after the financial markets close. The conference call will take place on the same day at 4:30 p.m. ET. The company focuses on developing medicines to target diseases driven by abnormally elevated aldosterone.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
-
-
Rhea-AI Summary
Mineralys Therapeutics, Inc. will be giving a presentation at the Jefferies Healthcare Conference on June 9, 2023. The live webcast can be accessed on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.61%
Tags
conferences
Rhea-AI Summary
Mineralys Therapeutics has announced the initiation of patient dosing in its lorundrostat pivotal clinical program for the treatment of uncontrolled or resistant hypertension. The company also plans to initiate a second pivotal trial and a Phase 2 trial to evaluate the safety and efficacy of lorundrostat. The topline data from the Advance-HTN trial is expected in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.57%
Tags
Mineralys Therapeutics, Inc.

Nasdaq:MLYS

MLYS Rankings

MLYS Stock Data

866.10M
61.04M
2%
87.07%
4.04%
Biotechnology
Pharmaceutical Preparations
Link
United States
RADNOR